Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin crossover study in adults with type 1 diabetes using continuous ketone monitoring
ACTRN12624000448549Phase 2Completed
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dapagliflozin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by St Vincent's Hospital Melbourne. Primary endpoints: Percentage time in range (3.9-10.0 mmol/L) on continuous glucose monitor and Number of episodes of diabetic ketoacidosis. Started Sep 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12624000448549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000448549.